GI
NTLA icon

GAMMA Investing’s Intellia Therapeutics NTLA Stock Holding History

GAMMA Investing’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.9K Sell
1,471
-208
-12% -$2.91K ﹤0.01% 2719
2026
Q1 		$21.5K Buy
1,679
+1,261
+302% +$16.1K ﹤0.01% 2676
2025
Q4 		$3.76K Sell
418
-124
-23% -$1.71K ﹤0.01% 3395
2025
Q3 		$9.36K Buy
542
+196
+57% +$2.41K ﹤0.01% 2911
2025
Q2 		$3.25K Sell
346
-715
-67% -$5.87K ﹤0.01% 3268
2025
Q1 		$7.54K Buy
1,061
+695
+190% +$7.02K ﹤0.01% 2882
2024
Q4 		$4.27K Buy
366
+149
+69% +$2.33K ﹤0.01% 2983
2024
Q3 		$4.46K Sell
217
-2,428
-92% -$56K ﹤0.01% 2789
2024
Q2 		$59.2K Buy
2,645
+2,459
+1,322% +$58.5K 0.01% 1078
2024
Q1 		$5.12K Buy
186
+63
+51% +$1.75K ﹤0.01% 2401
2023
Q4 		$2.93K Buy
+123
New +$3.54K ﹤0.01% 2451

Other funds holding NTLA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

GAMMA Investing's NTLA Position: Q2 2026 in Review

GAMMA Investing reduced its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, selling an estimated $2.91K and leaving 1,471 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

GAMMA Investing first reported a position in NTLA in Q4 2023 and has held it in 11 quarters since. The position peaked at $59.2K in Q2 2024. 29 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GAMMA Investing held 1,471 shares of Intellia Therapeutics worth $24.9K as of Q2 2026.
  • GAMMA Investing sold 208 Intellia Therapeutics shares in Q2 2026, an estimated $2.91K.
  • Intellia Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2719 holding.
  • GAMMA Investing first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Intellia Therapeutics position peaked at $59.2K in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.